CLINICAL TRIALS PROFILE FOR FAMOTIDINE; IBUPROFEN
✉ Email this page to a colleague
All Clinical Trials for famotidine; ibuprofen
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00450216 ↗ | Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 | 2007-03-01 | The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen. |
| NCT00450658 ↗ | Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 | 2007-03-01 | The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen. |
| NCT00613106 ↗ | Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 | 2007-09-01 | The purpose of this study is to evaluate the safety of long-term treatment with HZT-501. |
| NCT00984815 ↗ | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 | 2009-09-01 | The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment. |
| NCT01563185 ↗ | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | Completed | Pediatric Rheumatology Collaborative Study Group | Phase 4 | 2012-04-01 | The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks. |
| NCT01563185 ↗ | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | Completed | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 | 2012-04-01 | The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for famotidine; ibuprofen
Condition Name
Clinical Trial Locations for famotidine; ibuprofen
Trials by Country
Clinical Trial Progress for famotidine; ibuprofen
Clinical Trial Phase
Clinical Trial Sponsors for famotidine; ibuprofen
Sponsor Name
